#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


1-1	0-6	Unseen	_
1-2	7-12	scars	_
1-3	13-14	:	_
1-4	15-22	Cocaine	_
1-5	23-31	patients	_
1-6	32-36	with	_
1-7	37-42	prior	_
1-8	43-49	trauma	_
1-9	50-58	evidence	_
1-10	59-69	heightened	_
1-11	70-77	resting	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalCapacityRatingScale
1-12	78-83	state	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalCapacityRatingScale
1-13	84-94	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalCapacityRatingScale
1-14	95-107	connectivity	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalCapacityRatingScale
1-15	108-109	(	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalCapacityRatingScale
1-16	110-114	RSFC	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalCapacityRatingScale
1-17	115-116	)	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalCapacityRatingScale
1-18	117-124	between	_
1-19	125-128	the	_
1-20	129-137	amygdala	_
1-21	138-141	and	_
1-22	142-157	limbic-striatal	_
1-23	158-165	regions	_
1-24	166-176	Background	_
1-25	177-186	Substance	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder
1-26	187-190	use	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder
1-27	191-199	disorder	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder
1-28	200-201	(	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder
1-29	202-205	SUD	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder
1-30	206-207	)	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder
1-31	208-216	patients	_
1-32	217-221	with	_
1-33	222-223	a	_
1-34	224-231	history	_
1-35	232-234	of	_
1-36	235-241	trauma	_
1-37	242-249	exhibit	_
1-38	250-256	poorer	_
1-39	257-266	treatment	_
1-40	267-274	outcome	_
1-41	275-276	,	_
1-42	277-284	greater	_
1-43	285-295	functional	_
1-44	296-306	impairment	_
1-45	307-310	and	_
1-46	311-317	higher	_
1-47	318-322	risk	_
1-48	323-326	for	_
1-49	327-334	relapse	_
1-50	335-336	.	_

2-1	337-348	Endorsement	_
2-2	349-351	of	_
2-3	352-357	prior	_
2-4	358-364	trauma	_
2-5	365-368	has	_
2-6	369-370	,	_
2-7	371-373	in	_
2-8	374-381	several	_
2-9	382-385	SUD	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder
2-10	386-397	populations	_
2-11	398-399	,	_
2-12	400-404	been	_
2-13	405-411	linked	_
2-14	412-414	to	_
2-15	415-423	abnormal	_
2-16	424-434	functional	_
2-17	435-447	connectivity	_
2-18	448-449	(	_
2-19	450-452	FC	_
2-20	453-454	)	_
2-21	455-461	during	_
2-22	462-472	task-based	_
2-23	473-480	studies	_
2-24	481-482	.	_

3-1	483-485	We	_
3-2	486-494	examined	_
3-3	495-503	amygdala	_
3-4	504-506	FC	_
3-5	507-509	in	_
3-6	510-513	the	_
3-7	514-521	resting	_
3-8	522-527	state	_
3-9	528-529	(	_
3-10	530-532	RS	_
3-11	533-534	)	_
3-12	535-536	,	_
3-13	537-544	testing	_
3-14	545-548	for	_
3-15	549-560	differences	_
3-16	561-568	between	_
3-17	569-576	cocaine	_
3-18	577-585	patients	_
3-19	586-590	with	_
3-20	591-594	and	_
3-21	595-602	without	_
3-22	603-608	prior	_
3-23	609-615	trauma	_
3-24	616-617	.	_

4-1	618-625	Methods	http://maven.renci.org/NeuroBridge/neurobridge#DataCollectionMethod
4-2	626-634	Patients	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse
4-3	635-639	with	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse
4-4	640-647	cocaine	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse
4-5	648-651	use	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse
4-6	652-660	disorder	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse
4-7	661-662	(	_
4-8	663-666	CUD	_
4-9	667-668	;	_
4-10	669-673	n=34	_
4-11	674-675	)	_
4-12	676-680	were	_
4-13	681-691	stabilized	_
4-14	692-694	in	_
4-15	695-697	an	_
4-16	698-707	inpatient	_
4-17	708-715	setting	_
4-18	716-721	prior	_
4-19	722-724	to	_
4-20	725-726	a	_
4-21	727-731	BOLD	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
4-22	732-736	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
4-23	737-741	scan	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
4-24	742-743	.	_

5-1	744-753	Responses	_
5-2	754-756	to	_
5-3	757-766	Addiction	http://maven.renci.org/NeuroBridge/neurobridge#AddictionSeverityIndex
5-4	767-775	Severity	http://maven.renci.org/NeuroBridge/neurobridge#AddictionSeverityIndex
5-5	776-781	Index	http://maven.renci.org/NeuroBridge/neurobridge#AddictionSeverityIndex
5-6	782-785	and	_
5-7	786-789	the	_
5-8	790-808	Mini-International	http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale
5-9	809-825	Neuropsychiatric	http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale
5-10	826-835	Interview	http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale
5-11	836-840	were	_
5-12	841-845	used	_
5-13	846-848	to	_
5-14	849-861	characterize	_
5-15	862-865	the	_
5-16	866-875	No-Trauma	_
5-17	876-877	(	_
5-18	878-882	n=16	_
5-19	883-884	)	_
5-20	885-888	and	_
5-21	889-895	Trauma	_
5-22	896-897	(	_
5-23	898-902	n=18	_
5-24	903-904	)	_
5-25	905-911	groups	_
5-26	912-913	.	_

6-1	914-924	Seed-based	_
6-2	925-929	RSFC	_
6-3	930-933	was	_
6-4	934-943	conducted	_
6-5	944-949	using	_
6-6	950-953	the	_
6-7	954-959	right	_
6-8	960-963	and	_
6-9	964-968	left	_
6-10	969-977	amygdala	_
6-11	978-980	as	_
6-12	981-988	regions	_
6-13	989-991	of	_
6-14	992-1000	interest	_
6-15	1001-1002	.	_

7-1	1003-1014	Examination	_
7-2	1015-1017	of	_
7-3	1018-1026	amygdala	_
7-4	1027-1031	RSFC	_
7-5	1032-1035	was	_
7-6	1036-1046	restricted	_
7-7	1047-1049	to	_
7-8	1050-1052	an	_
7-9	1053-1054	a	_
7-10	1055-1061	priori	_
7-11	1062-1072	anatomical	_
7-12	1073-1077	mask	_
7-13	1078-1082	that	_
7-14	1083-1095	incorporated	_
7-15	1096-1101	nodes	_
7-16	1102-1104	of	_
7-17	1105-1108	the	_
7-18	1109-1124	limbic-striatal	_
7-19	1125-1137	motivational	_
7-20	1138-1145	network	_
7-21	1146-1147	.	_

8-1	1148-1155	Results	_
8-2	1156-1160	RSFC	_
8-3	1161-1164	was	_
8-4	1165-1173	compared	_
8-5	1174-1177	for	_
8-6	1178-1181	the	_
8-7	1182-1188	Trauma	_
8-8	1189-1195	versus	_
8-9	1196-1205	No-Trauma	_
8-10	1206-1212	groups	_
8-11	1213-1214	.	_

9-1	1215-1218	The	_
9-2	1219-1225	Trauma	_
9-3	1226-1231	group	_
9-4	1232-1241	evidenced	_
9-5	1242-1249	greater	_
9-6	1250-1262	connectivity	_
9-7	1263-1270	between	_
9-8	1271-1274	the	_
9-9	1275-1283	amygdala	_
9-10	1284-1287	and	_
9-11	1288-1291	the	_
9-12	1292-1293	a	_
9-13	1294-1300	priori	_
9-14	1301-1316	limbic-striatal	_
9-15	1317-1321	mask	_
9-16	1322-1323	.	_

10-1	1324-1329	Peaks	_
10-2	1330-1336	within	_
10-3	1337-1340	the	_
10-4	1341-1354	statistically	_
10-5	1355-1366	significant	_
10-6	1367-1382	limbic-striatal	_
10-7	1383-1387	mask	_
10-8	1388-1396	included	_
10-9	1397-1400	the	_
10-10	1401-1409	amygdala	_
10-11	1410-1411	,	_
10-12	1412-1419	putamen	_
10-13	1420-1421	,	_
10-14	1422-1430	pallidum	_
10-15	1431-1432	,	_
10-16	1433-1440	caudate	_
10-17	1441-1442	,	_
10-18	1443-1451	thalamus	_
10-19	1452-1453	,	_
10-20	1454-1460	insula	_
10-21	1461-1462	,	_
10-22	1463-1490	hippocampus/parahippocampus	_
10-23	1491-1492	,	_
10-24	1493-1496	and	_
10-25	1497-1502	brain	_
10-26	1503-1507	stem	_
10-27	1508-1509	.	_

11-1	1510-1521	Conclusions	_
11-2	1522-1529	Results	_
11-3	1530-1537	suggest	_
11-4	1538-1542	that	_
11-5	1543-1550	cocaine	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
11-6	1551-1559	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
11-7	1560-1564	with	_
11-8	1565-1570	prior	_
11-9	1571-1577	trauma	_
11-10	1578-1579	(	_
11-11	1580-1586	versus	_
11-12	1587-1594	without	_
11-13	1595-1596	)	_
11-14	1597-1601	have	_
11-15	1602-1612	heightened	_
11-16	1613-1626	communication	_
11-17	1627-1633	within	_
11-18	1634-1639	nodes	_
11-19	1640-1642	of	_
11-20	1643-1646	the	_
11-21	1647-1659	motivational	_
11-22	1660-1667	network	_
11-23	1668-1669	,	_
11-24	1670-1674	even	_
11-25	1675-1677	at	_
11-26	1678-1682	rest	_
11-27	1683-1684	.	_

12-1	1685-1687	To	_
12-2	1688-1691	our	_
12-3	1692-1701	knowledge	_
12-4	1702-1703	,	_
12-5	1704-1708	this	_
12-6	1709-1711	is	_
12-7	1712-1715	the	_
12-8	1716-1721	first	_
12-9	1722-1726	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
12-10	1727-1732	study	_
12-11	1733-1735	to	_
12-12	1736-1743	examine	_
12-13	1744-1752	amygdala	_
12-14	1753-1757	RSFC	_
12-15	1758-1763	among	_
12-16	1764-1769	those	_
12-17	1770-1774	with	_
12-18	1775-1778	CUD	_
12-19	1779-1782	and	_
12-20	1783-1789	trauma	_
12-21	1790-1797	history	_
12-22	1798-1799	.	_

13-1	1800-1810	Heightened	_
13-2	1811-1815	RSFC	_
13-3	1816-1827	intralimbic	_
13-4	1828-1840	connectivity	_
13-5	1841-1844	for	_
13-6	1845-1848	the	_
13-7	1849-1855	Trauma	_
13-8	1856-1861	group	_
13-9	1862-1865	may	_
13-10	1866-1873	reflect	_
13-11	1874-1875	a	_
13-12	1876-1892	relapse-relevant	_
13-13	1893-1898	brain	_
13-14	1899-1912	vulnerability	_
13-15	1913-1916	and	_
13-16	1917-1918	a	_
13-17	1919-1924	novel	_
13-18	1925-1934	treatment	_
13-19	1935-1941	target	_
13-20	1942-1945	for	_
13-21	1946-1950	this	_
13-22	1951-1973	clinically-challenging	_
13-23	1974-1984	population	_
13-24	1985-1986	.	_

14-1	1987-1988	2	_
14-2	1989-1990	.	_

15-1	1991-1998	Methods	http://maven.renci.org/NeuroBridge/neurobridge#DataCollectionMethod
15-2	1999-2002	2.1	_
15-3	2003-2015	Participants	_
15-4	2016-2028	Participants	_
15-5	2029-2033	were	_
15-6	2034-2036	34	_
15-7	2037-2054	treatment-seeking	http://maven.renci.org/NeuroBridge/neurobridge#TreatmentResponseProgressScale
15-8	2055-2056	,	http://maven.renci.org/NeuroBridge/neurobridge#TreatmentResponseProgressScale
15-9	2057-2074	cocaine-dependent	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse
15-10	2075-2078	men	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse
15-11	2079-2080	,	_
15-12	2081-2088	between	_
15-13	2089-2091	34	_
15-14	2092-2095	and	_
15-15	2096-2098	60	_
15-16	2099-2104	years	_
15-17	2105-2107	of	_
15-18	2108-2111	age	_
15-19	2112-2113	,	_
15-20	2114-2117	who	_
15-21	2118-2121	met	_
15-22	2122-2128	DSM-IV	_
15-23	2129-2137	criteria	_
15-24	2138-2141	for	_
15-25	2142-2149	cocaine	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse
15-26	2150-2160	dependence	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse
15-27	2161-2162	,	_
15-28	2163-2172	described	_
15-29	2173-2180	smoking	_
15-30	2181-2183	as	_
15-31	2184-2189	their	_
15-32	2190-2197	primary	_
15-33	2198-2203	route	_
15-34	2204-2206	of	_
15-35	2207-2220	cocaine-crack	_
15-36	2221-2235	administration	_
15-37	2236-2237	,	_
15-38	2238-2241	and	_
15-39	2242-2250	reported	_
15-40	2251-2256	using	_
15-41	2257-2264	cocaine	_
15-42	2265-2267	on	_
15-43	2268-2270	at	_
15-44	2271-2276	least	_
15-45	2277-2278	8	_
15-46	2279-2281	of	_
15-47	2282-2285	the	_
15-48	2286-2288	30	_
15-49	2289-2293	days	_
15-50	2294-2300	before	_
15-51	2301-2310	screening	_
15-52	2311-2312	(	_
15-53	2313-2316	See	_
15-54	2317-2322	Table	_
15-55	2323-2324	1	_
15-56	2325-2328	for	_
15-57	2329-2341	demographics	_
15-58	2342-2343	)	_
15-59	2344-2345	.	_

16-1	2346-2358	Participants	_
16-2	2359-2363	were	_
16-3	2364-2373	recruited	_
16-4	2374-2381	through	_
16-5	2382-2396	advertisements	_
16-6	2397-2399	in	_
16-7	2400-2405	local	_
16-8	2406-2411	media	_
16-9	2412-2415	and	_
16-10	2416-2420	were	_
16-11	2421-2425	part	_
16-12	2426-2428	of	_
16-13	2429-2430	a	_
16-14	2431-2437	larger	_
16-15	2438-2443	study	_
16-16	2444-2453	examining	_
16-17	2454-2459	brain	_
16-18	2460-2463	and	_
16-19	2464-2474	behavioral	_
16-20	2475-2490	vulnerabilities	_
16-21	2491-2501	associated	_
16-22	2502-2506	with	_
16-23	2507-2516	addiction	_
16-24	2517-2518	.	_

17-1	2519-2524	After	_
17-2	2525-2535	completing	_
17-3	2536-2537	a	_
17-4	2538-2546	detailed	_
17-5	2547-2556	telephone	_
17-6	2557-2563	screen	_
17-7	2564-2565	,	_
17-8	2566-2578	participants	_
17-9	2579-2587	provided	_
17-10	2588-2596	informed	_
17-11	2597-2604	consent	_
17-12	2605-2606	,	_
17-13	2607-2611	were	_
17-14	2612-2621	medically	_
17-15	2622-2630	screened	_
17-16	2631-2632	,	_
17-17	2633-2636	and	_
17-18	2637-2646	completed	_
17-19	2647-2660	psychological	_
17-20	2661-2671	assessment	_
17-21	2672-2680	measures	_
17-22	2681-2682	.	_

18-1	2683-2692	Exclusion	_
18-2	2693-2701	criteria	_
18-3	2702-2710	included	_
18-4	2711-2712	:	_
18-5	2713-2730	contraindications	_
18-6	2731-2734	for	_
18-7	2735-2739	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
18-8	2740-2741	(	_
18-9	2742-2746	e.g.	_
18-10	2747-2748	,	_
18-11	2749-2754	metal	_
18-12	2755-2757	in	_
18-13	2758-2761	the	_
18-14	2762-2766	body	_
18-15	2767-2768	,	_
18-16	2769-2783	claustrophobia	_
18-17	2784-2785	)	_
18-18	2786-2787	,	_
18-19	2788-2791	use	_
18-20	2792-2794	of	_
18-21	2795-2806	medications	_
18-22	2807-2816	affecting	_
18-23	2817-2824	central	_
18-24	2825-2837	dopaminergic	_
18-25	2838-2855	neurotransmission	_
18-26	2856-2857	,	_
18-27	2858-2865	history	_
18-28	2866-2868	of	_
18-29	2869-2878	psychosis	_
18-30	2879-2880	,	_
18-31	2881-2889	seizures	_
18-32	2890-2891	,	_
18-33	2892-2894	or	_
18-34	2895-2902	organic	_
18-35	2903-2908	brain	_
18-36	2909-2917	syndrome	_
18-37	2918-2927	unrelated	_
18-38	2928-2930	to	_
18-39	2931-2938	cocaine	_
18-40	2939-2942	use	_
18-41	2943-2944	,	_
18-42	2945-2955	clinically	_
18-43	2956-2967	significant	_
18-44	2968-2982	cardiovascular	_
18-45	2983-2984	,	_
18-46	2985-2996	hematologic	_
18-47	2997-2998	,	_
18-48	2999-3006	hepatic	_
18-49	3007-3008	,	_
18-50	3009-3014	renal	_
18-51	3015-3016	,	_
18-52	3017-3029	neurological	_
18-53	3030-3031	,	_
18-54	3032-3034	or	_
18-55	3035-3044	endocrine	_
18-56	3045-3058	abnormalities	_
18-57	3059-3060	,	_
18-58	3061-3068	history	_
18-59	3069-3071	of	_
18-60	3072-3076	head	_
18-61	3077-3083	trauma	_
18-62	3084-3086	or	_
18-63	3087-3091	loss	_
18-64	3092-3094	of	_
18-65	3095-3108	consciousness	_
18-66	3109-3112	for	_
18-67	3113-3117	more	_
18-68	3118-3122	than	_
18-69	3123-3124	3	_
18-70	3125-3132	minutes	_
18-71	3133-3134	.	_

19-1	3135-3146	Psychiatric	_
19-2	3147-3156	diagnoses	_
19-3	3157-3161	were	_
19-4	3162-3167	based	_
19-5	3168-3170	on	_
19-6	3171-3174	the	_
19-7	3175-3179	Mini	_
19-8	3180-3193	International	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
19-9	3194-3210	Neuropsychiatric	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
19-10	3211-3220	Interview	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
19-11	3221-3222	(	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
19-12	3223-3227	MINI	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
19-13	3228-3229	)	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
19-14	3230-3233	and	_
19-15	3234-3239	those	_
19-16	3240-3249	diagnosed	_
19-17	3250-3254	with	_
19-18	3255-3263	comorbid	_
19-19	3264-3268	Axis	_
19-20	3269-3270	I	_
19-21	3271-3280	disorders	_
19-22	3281-3285	were	_
19-23	3286-3294	excluded	_
19-24	3295-3296	,	_
19-25	3297-3301	with	_
19-26	3302-3311	exception	_
19-27	3312-3315	for	_
19-28	3316-3326	dependence	_
19-29	3327-3329	on	_
19-30	3330-3338	nicotine	_
19-31	3339-3340	,	_
19-32	3341-3350	marijuana	_
19-33	3351-3352	,	_
19-34	3353-3355	or	_
19-35	3356-3363	alcohol	_
19-36	3364-3367	not	_
19-37	3368-3377	requiring	_
19-38	3378-3385	medical	_
19-39	3386-3400	detoxification	_
19-40	3401-3402	.	_

20-1	3403-3415	Participants	_
20-2	3416-3423	meeting	_
20-3	3424-3434	diagnostic	_
20-4	3435-3443	criteria	_
20-5	3444-3447	for	_
20-6	3448-3458	depression	_
20-7	3459-3463	were	_
20-8	3464-3467	not	_
20-9	3468-3476	excluded	_
20-10	3477-3479	if	_
20-11	3480-3485	their	_
20-12	3486-3495	diagnosis	_
20-13	3496-3499	was	_
20-14	3500-3506	linked	_
20-15	3507-3513	solely	_
20-16	3514-3516	to	_
20-17	3517-3524	periods	_
20-18	3525-3527	of	_
20-19	3528-3535	cocaine	_
20-20	3536-3549	use/cessation	_
20-21	3550-3551	.	_

21-1	3552-3556	This	_
21-2	3557-3562	study	_
21-3	3563-3570	adhered	_
21-4	3571-3573	to	_
21-5	3574-3577	the	_
21-6	3578-3589	Declaration	_
21-7	3590-3592	of	_
21-8	3593-3601	Helsinki	_
21-9	3602-3605	and	_
21-10	3606-3609	was	_
21-11	3610-3618	approved	_
21-12	3619-3621	by	_
21-13	3622-3625	the	_
21-14	3626-3636	University	_
21-15	3637-3639	of	_
21-16	3640-3652	Pennsylvania	_
21-17	3653-3666	Institutional	_
21-18	3667-3673	Review	_
21-19	3674-3679	Board	_
21-20	3680-3681	.	_

22-1	3682-3685	2.2	_
22-2	3686-3687	.	_

23-1	3688-3693	Study	_
23-2	3694-3700	Design	_
23-3	3701-3713	Participants	_
23-4	3714-3718	were	_
23-5	3719-3729	stabilized	_
23-6	3730-3732	in	_
23-7	3733-3734	a	_
23-8	3735-3745	supervised	_
23-9	3746-3755	drug-free	_
23-10	3756-3767	residential	_
23-11	3768-3781	stabilization	_
23-12	3782-3786	unit	_
23-13	3787-3790	for	_
23-14	3791-3795	7–10	_
23-15	3796-3800	days	_
23-16	3801-3806	prior	_
23-17	3807-3809	to	_
23-18	3810-3823	participating	_
23-19	3824-3826	in	_
23-20	3827-3828	a	_
23-21	3829-3837	one-hour	_
23-22	3838-3842	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
23-23	3843-3851	scanning	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
23-24	3852-3859	session	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
23-25	3860-3869	involving	_
23-26	3870-3877	several	_
23-27	3878-3890	experimental	_
23-28	3891-3896	tasks	_
23-29	3897-3906	including	_
23-30	3907-3908	a	_
23-31	3909-3913	BOLD	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
23-32	3914-3921	resting	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
23-33	3922-3927	state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
23-34	3928-3932	scan	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
23-35	3933-3934	,	_
23-36	3935-3940	which	_
23-37	3941-3949	preceded	_
23-38	3950-3953	the	_
23-39	3954-3964	behavioral	_
23-40	3965-3970	tasks	_
23-41	3971-3972	.	_

24-1	3973-3977	This	_
24-2	3978-3988	controlled	_
24-3	3989-3996	setting	_
24-4	3997-4007	eliminates	_
24-5	4008-4011	the	_
24-6	4012-4018	impact	_
24-7	4019-4021	of	_
24-8	4022-4029	cocaine	_
24-9	4030-4042	intoxication	_
24-10	4043-4046	and	_
24-11	4047-4056	minimizes	_
24-12	4057-4060	the	_
24-13	4061-4073	contribution	_
24-14	4074-4076	of	_
24-15	4077-4086	cessation	_
24-16	4087-4095	symptoms	_
24-17	4096-4098	to	_
24-18	4099-4104	study	_
24-19	4105-4113	measures	_
24-20	4114-4115	.	_

25-1	4116-4119	2.3	_
25-2	4120-4121	.	_

26-1	4122-4130	Measures	_
26-2	4131-4138	Cocaine	_
26-3	4139-4142	and	_
26-4	4143-4148	other	_
26-5	4149-4156	illicit	_
26-6	4157-4161	drug	_
26-7	4162-4165	use	_
26-8	4166-4169	for	_
26-9	4170-4173	the	_
26-10	4174-4178	past	_
26-11	4179-4181	30	_
26-12	4182-4186	days	_
26-13	4187-4191	were	_
26-14	4192-4200	assessed	_
26-15	4201-4205	with	_
26-16	4206-4209	the	_
26-17	4210-4219	Addiction	http://maven.renci.org/NeuroBridge/neurobridge#AddictionSeverityIndex
26-18	4220-4228	Severity	http://maven.renci.org/NeuroBridge/neurobridge#AddictionSeverityIndex
26-19	4229-4234	Index	http://maven.renci.org/NeuroBridge/neurobridge#AddictionSeverityIndex
26-20	4235-4236	(	http://maven.renci.org/NeuroBridge/neurobridge#AddictionSeverityIndex
26-21	4237-4240	ASI	http://maven.renci.org/NeuroBridge/neurobridge#AddictionSeverityIndex
26-22	4241-4242	)	http://maven.renci.org/NeuroBridge/neurobridge#AddictionSeverityIndex
26-23	4243-4246	and	_
26-24	4247-4250	the	_
26-25	4251-4259	Timeline	http://maven.renci.org/NeuroBridge/neurobridge#TimeIntervalUnit
26-26	4260-4270	Followback	http://maven.renci.org/NeuroBridge/neurobridge#TimeIntervalUnit
26-27	4271-4280	interview	http://maven.renci.org/NeuroBridge/neurobridge#TimeIntervalUnit
26-28	4281-4282	(	http://maven.renci.org/NeuroBridge/neurobridge#TimeIntervalUnit
26-29	4283-4287	TLFB	http://maven.renci.org/NeuroBridge/neurobridge#TimeIntervalUnit
26-30	4288-4289	)	http://maven.renci.org/NeuroBridge/neurobridge#TimeIntervalUnit
26-31	4290-4291	.	_

27-1	4292-4300	Presence	_
27-2	4301-4303	of	_
27-3	4304-4315	psychiatric	_
27-4	4316-4325	diagnosis	_
27-5	4326-4329	was	_
27-6	4330-4335	based	_
27-7	4336-4338	on	_
27-8	4339-4346	results	_
27-9	4347-4351	from	_
27-10	4352-4355	the	_
27-11	4356-4360	MINI	_
27-12	4361-4362	.	_

28-1	4363-4365	To	_
28-2	4366-4372	assess	_
28-3	4373-4376	for	_
28-4	4377-4383	recent	_
28-5	4384-4391	anxiety	_
28-6	4392-4395	and	_
28-7	4396-4406	depression	_
28-8	4407-4408	,	_
28-9	4409-4419	additional	_
28-10	4420-4428	measures	_
28-11	4429-4437	included	_
28-12	4438-4441	the	_
28-13	4442-4446	Beck	http://maven.renci.org/NeuroBridge/neurobridge#TraitAnxietyInventory
28-14	4447-4454	Anxiety	http://maven.renci.org/NeuroBridge/neurobridge#TraitAnxietyInventory
28-15	4455-4464	Inventory	http://maven.renci.org/NeuroBridge/neurobridge#TraitAnxietyInventory
28-16	4465-4466	(	http://maven.renci.org/NeuroBridge/neurobridge#TraitAnxietyInventory
28-17	4467-4470	BAI	http://maven.renci.org/NeuroBridge/neurobridge#TraitAnxietyInventory
28-18	4471-4472	)	http://maven.renci.org/NeuroBridge/neurobridge#TraitAnxietyInventory
28-19	4473-4474	,	_
28-20	4475-4478	the	_
28-21	4479-4483	Beck	http://maven.renci.org/NeuroBridge/neurobridge#BeckDepressionInventory
28-22	4484-4494	Depression	http://maven.renci.org/NeuroBridge/neurobridge#BeckDepressionInventory
28-23	4495-4504	Inventory	http://maven.renci.org/NeuroBridge/neurobridge#BeckDepressionInventory
28-24	4505-4506	(	http://maven.renci.org/NeuroBridge/neurobridge#BeckDepressionInventory
28-25	4507-4510	BDI	http://maven.renci.org/NeuroBridge/neurobridge#BeckDepressionInventory
28-26	4511-4512	)	http://maven.renci.org/NeuroBridge/neurobridge#BeckDepressionInventory
28-27	4513-4514	,	_
28-28	4515-4518	and	_
28-29	4519-4522	the	_
28-30	4523-4532	clinician	_
28-31	4533-4545	administered	_
28-32	4546-4547	,	_
28-33	4548-4556	Hamilton	http://maven.renci.org/NeuroBridge/neurobridge#DepressionRatingScale
28-34	4557-4563	Rating	http://maven.renci.org/NeuroBridge/neurobridge#DepressionRatingScale
28-35	4564-4569	Scale	http://maven.renci.org/NeuroBridge/neurobridge#DepressionRatingScale
28-36	4570-4573	for	http://maven.renci.org/NeuroBridge/neurobridge#DepressionRatingScale
28-37	4574-4584	Depression	http://maven.renci.org/NeuroBridge/neurobridge#DepressionRatingScale
28-38	4585-4586	(	http://maven.renci.org/NeuroBridge/neurobridge#DepressionRatingScale
28-39	4587-4592	HAM-D	http://maven.renci.org/NeuroBridge/neurobridge#DepressionRatingScale
28-40	4593-4594	)	http://maven.renci.org/NeuroBridge/neurobridge#DepressionRatingScale
28-41	4595-4596	.	_

29-1	4597-4600	The	_
29-2	4601-4605	PTSD	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence
29-3	4606-4615	Checklist	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence
29-4	4616-4619	for	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence
29-5	4620-4629	Civilians	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence
29-6	4630-4631	(	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence
29-7	4632-4637	PCL-C	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence
29-8	4638-4639	)	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence
29-9	4640-4643	was	_
29-10	4644-4648	also	_
29-11	4649-4661	administered	_
29-12	4662-4664	to	_
29-13	4665-4677	characterize	_
29-14	4678-4686	symptoms	_
29-15	4687-4691	that	_
29-16	4692-4695	may	_
29-17	4696-4705	accompany	_
29-18	4706-4712	trauma	_
29-19	4713-4721	exposure	_
29-20	4722-4724	as	_
29-21	4725-4726	a	_
29-22	4727-4736	potential	_
29-23	4737-4745	clinical	_
29-24	4746-4755	validator	_
29-25	4756-4759	for	_
29-26	4760-4763	the	_
29-27	4764-4770	Trauma	_
29-28	4771-4779	subgroup	_
29-29	4780-4781	.	_

30-1	4782-4794	Participants	_
30-2	4795-4804	completed	_
30-3	4805-4813	measures	_
30-4	4814-4820	during	_
30-5	4821-4826	their	_
30-6	4827-4834	initial	_
30-7	4835-4844	screening	_
30-8	4845-4855	assessment	_
30-9	4856-4857	(	_
30-10	4858-4863	PCL-C	_
30-11	4864-4865	,	_
30-12	4866-4870	MINI	_
30-13	4871-4872	,	_
30-14	4873-4876	ASI	_
30-15	4877-4878	)	_
30-16	4879-4882	and	_
30-17	4883-4888	their	_
30-18	4889-4897	baseline	_
30-19	4898-4903	visit	_
30-20	4904-4905	(	_
30-21	4906-4909	BAI	_
30-22	4910-4911	,	_
30-23	4912-4915	BDI	_
30-24	4916-4917	,	_
30-25	4918-4923	HAM-D	_
30-26	4924-4925	,	_
30-27	4926-4930	TLFB	_
30-28	4931-4932	)	_
30-29	4933-4934	.	_

31-1	4935-4939	2.4.	_
31-2	4940-4944	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
31-3	4945-4956	Acquisition	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
31-4	4957-4967	Functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
31-5	4968-4970	MR	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
31-6	4971-4978	imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
31-7	4979-4982	was	_
31-8	4983-4992	conducted	_
31-9	4993-4995	on	_
31-10	4996-4997	a	_
31-11	4998-5001	3-T	_
31-12	5002-5012	whole-body	_
31-13	5013-5020	scanner	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse
31-14	5021-5022	(	_
31-15	5023-5030	Siemens	_
31-16	5031-5034	Tim	_
31-17	5035-5039	Trio	_
31-18	5040-5041	,	_
31-19	5042-5050	Erlangen	_
31-20	5051-5052	,	_
31-21	5053-5060	Germany	_
31-22	5061-5062	)	_
31-23	5063-5064	.	_

32-1	5065-5080	High-resolution	http://maven.renci.org/NeuroBridge/neurobridge#HighRisk
32-2	5081-5091	structural	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
32-3	5092-5098	images	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
32-4	5099-5103	were	_
32-5	5104-5112	acquired	_
32-6	5113-5116	for	_
32-7	5117-5124	spatial	_
32-8	5125-5130	brain	_
32-9	5131-5144	normalization	_
32-10	5145-5150	using	_
32-11	5151-5152	a	_
32-12	5153-5155	3D	_
32-13	5156-5169	magnetization	_
32-14	5170-5178	prepared	_
32-15	5179-5184	rapid	_
32-16	5185-5193	gradient	_
32-17	5194-5198	echo	_
32-18	5199-5200	(	_
32-19	5201-5207	MPRAGE	http://maven.renci.org/NeuroBridge/neurobridge#Age
32-20	5208-5209	)	http://maven.renci.org/NeuroBridge/neurobridge#Age
32-21	5210-5218	sequence	_
32-22	5219-5220	(	_
32-23	5221-5229	TR/TE/TI	_
32-24	5230-5231	=	_
32-25	5232-5244	1620/3/950ms	_
32-26	5245-5246	)	_
32-27	5247-5248	.	_

33-1	5249-5255	Images	_
33-2	5256-5259	for	_
33-3	5260-5263	the	_
33-4	5264-5276	resting-scan	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
33-5	5277-5281	were	_
33-6	5282-5290	acquired	_
33-7	5291-5297	during	_
33-8	5298-5299	a	_
33-9	5300-5305	6-min	_
33-10	5306-5310	scan	_
33-11	5311-5316	using	_
33-12	5317-5318	a	_
33-13	5319-5332	gradient-echo	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
33-14	5333-5352	echo-planar-imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
33-15	5353-5361	sequence	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
33-16	5362-5363	(	_
33-17	5364-5369	TR/TE	_
33-18	5370-5371	=	_
33-19	5372-5379	2s/30ms	_
33-20	5380-5381	,	_
33-21	5382-5385	FOV	_
33-22	5386-5387	=	_
33-23	5388-5395	220x220	_
33-24	5396-5399	mm2	_
33-25	5400-5401	,	_
33-26	5402-5408	matrix	_
33-27	5409-5410	=	_
33-28	5411-5416	64x64	_
33-29	5417-5418	,	_
33-30	5419-5424	slice	_
33-31	5425-5434	thickness	_
33-32	5435-5436	=	_
33-33	5437-5440	4.5	_
33-34	5441-5443	mm	_
33-35	5444-5445	,	_
33-36	5446-5449	150	_
33-37	5450-5456	images	_
33-38	5457-5461	were	_
33-39	5462-5470	acquired	_
33-40	5471-5472	)	_
33-41	5473-5474	.	_

34-1	5475-5487	Participants	_
34-2	5488-5492	were	_
34-3	5493-5498	asked	_
34-4	5499-5501	to	_
34-5	5502-5508	remain	_
34-6	5509-5514	still	_
34-7	5515-5519	with	_
34-8	5520-5525	their	_
34-9	5526-5530	eyes	_
34-10	5531-5535	open	_
34-11	5536-5539	and	_
34-12	5540-5542	to	_
34-13	5543-5546	not	_
34-14	5547-5552	think	_
34-15	5553-5558	about	_
34-16	5559-5567	anything	_
34-17	5568-5570	in	_
34-18	5571-5581	particular	_
34-19	5582-5588	during	_
34-20	5589-5593	this	_
34-21	5594-5598	scan	_
34-22	5599-5600	.	_

35-1	5601-5605	Data	_
35-2	5606-5619	preprocessing	_
35-3	5620-5623	was	_
35-4	5624-5631	carried	_
35-5	5632-5635	out	_
35-6	5636-5641	using	_
35-7	5642-5646	Data	_
35-8	5647-5657	Processing	_
35-9	5658-5667	Assistant	_
35-10	5668-5671	for	_
35-11	5672-5685	Resting-State	_
35-12	5686-5690	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
35-13	5691-5696	Basic	_
35-14	5697-5704	Edition	_
35-15	5705-5706	(	_
35-16	5707-5713	DPARSF	_
35-17	5714-5715	)	_
35-18	5716-5719	and	_
35-19	5720-5724	Data	_
35-20	5725-5735	Processing	_
35-21	5736-5739	and	_
35-22	5740-5748	Analysis	_
35-23	5749-5751	of	_
35-24	5752-5757	Brain	_
35-25	5758-5765	Imaging	_
35-26	5766-5767	(	_
35-27	5768-5772	REST	_
35-28	5773-5774	)	_
35-29	5775-5782	toolbox	_
35-30	5783-5784	,	_
35-31	5785-5790	based	_
35-32	5791-5793	on	_
35-33	5794-5798	SPM8	_
35-34	5799-5800	(	_
35-35	5801-5805	http	_
35-36	5806-5807	:	_
35-37	5808-5835	//www.fil.ion.ucl.ac.uk/spm	_
35-38	5836-5837	)	_
35-39	5838-5841	run	_
35-40	5842-5847	under	_
35-41	5848-5854	Matlab	_
35-42	5855-5860	R2015	_
35-43	5861-5872	environment	_
35-44	5873-5874	.	_

36-1	5875-5877	In	_
36-2	5878-5882	this	_
36-3	5883-5888	paper	_
36-4	5889-5890	,	_
36-5	5891-5893	we	_
36-6	5894-5902	followed	_
36-7	5903-5906	the	_
36-8	5907-5915	standard	_
36-9	5916-5929	preprocessing	_
36-10	5930-5938	pipeline	_
36-11	5939-5944	still	_
36-12	5945-5955	accounting	_
36-13	5956-5959	for	_
36-14	5960-5966	motion	_
36-15	5967-5974	related	_
36-16	5975-5984	artifacts	_
36-17	5985-5986	.	_

37-1	5987-5991	Each	_
37-2	5992-6004	participants	_
37-3	6005-6006	’	_
37-4	6007-6013	images	_
37-5	6014-6018	were	_
37-6	6019-6029	slice-time	_
37-7	6030-6039	corrected	_
37-8	6040-6041	,	_
37-9	6042-6051	realigned	_
37-10	6052-6053	,	_
37-11	6054-6066	coregistered	_
37-12	6067-6069	to	_
37-13	6070-6085	high-resolution	_
37-14	6086-6096	structural	_
37-15	6097-6103	images	_
37-16	6104-6105	,	_
37-17	6106-6109	and	_
37-18	6110-6122	subsequently	_
37-19	6123-6133	normalized	_
37-20	6134-6136	to	_
37-21	6137-6140	MNI	_
37-22	6141-6149	standard	_
37-23	6150-6155	space	_
37-24	6156-6159	and	_
37-25	6160-6168	smoothed	_
37-26	6169-6173	with	_
37-27	6174-6177	the	_
37-28	6178-6182	FWHM	_
37-29	6183-6189	kernel	_
37-30	6190-6192	of	_
37-31	6193-6196	6mm	_
37-32	6197-6198	.	_

38-1	6199-6206	Summary	_
38-2	6207-6213	motion	_
38-3	6214-6224	statistics	_
38-4	6225-6228	for	_
38-5	6229-6233	each	_
38-6	6234-6241	subject	_
38-7	6242-6246	were	_
38-8	6247-6255	examined	_
38-9	6256-6259	and	_
38-10	6260-6269	confirmed	_
38-11	6270-6273	the	_
38-12	6274-6280	motion	_
38-13	6281-6284	was	_
38-14	6285-6290	below	_
38-15	6291-6294	2mm	_
38-16	6295-6297	in	_
38-17	6298-6302	both	_
38-18	6303-6313	directions	_
38-19	6314-6315	.	_

39-1	6316-6318	In	_
39-2	6319-6329	addressing	_
39-3	6330-6333	the	_
39-4	6334-6338	head	_
39-5	6339-6345	motion	_
39-6	6346-6354	concerns	_
39-7	6355-6356	,	_
39-8	6357-6359	we	_
39-9	6360-6369	regressed	_
39-10	6370-6373	out	_
39-11	6374-6381	Friston	_
39-12	6382-6384	24	_
39-13	6385-6389	head	_
39-14	6390-6396	motion	_
39-15	6397-6407	parameters	_
39-16	6408-6413	which	_
39-17	6414-6422	includes	_
39-18	6423-6426	six	_
39-19	6427-6431	head	_
39-20	6432-6438	motion	_
39-21	6439-6448	estimates	_
39-22	6449-6453	from	_
39-23	6454-6461	current	_
39-24	6462-6466	time	_
39-25	6467-6472	point	_
39-26	6473-6474	(	_
39-27	6475-6477	Rt	_
39-28	6478-6479	=	_
39-29	6480-6481	[	_
39-30	6482-6483	X	_
39-31	6484-6485	Y	_
39-32	6486-6487	Z	_
39-33	6488-6493	pitch	_
39-34	6494-6498	roll	_
39-35	6499-6502	yaw	_
39-36	6503-6504	]	_
39-37	6505-6506	)	_
39-38	6507-6508	,	_
39-39	6509-6512	six	_
39-40	6513-6517	head	_
39-41	6518-6524	motion	_
39-42	6525-6535	parameters	_
39-43	6536-6540	from	_
39-44	6541-6552	immediately	_
39-45	6553-6562	preceding	_
39-46	6563-6567	time	_
39-47	6568-6573	point	_
39-48	6574-6575	(	_
39-49	6576-6580	Rt-1	_
39-50	6581-6582	)	_
39-51	6583-6586	and	_
39-52	6587-6592	their	_
39-53	6593-6606	corresponding	_
39-54	6607-6614	squares	_
39-55	6615-6616	(	_
39-56	6617-6619	Rt	_
39-57	6620-6621	2	_
39-58	6622-6623	,	_
39-59	6624-6628	Rt-1	_
39-60	6629-6630	2	_
39-61	6631-6632	)	_
39-62	6633-6634	.	_

40-1	6635-6640	Given	_
40-2	6641-6644	the	_
40-3	6645-6653	concerns	_
40-4	6654-6656	of	_
40-5	6657-6660	the	_
40-6	6661-6666	field	_
40-7	6667-6672	about	_
40-8	6673-6676	the	_
40-9	6677-6683	impact	_
40-10	6684-6686	of	_
40-11	6687-6692	micro	_
40-12	6693-6699	motion	_
40-13	6700-6701	(	_
40-14	6702-6704	as	_
40-15	6705-6710	small	_
40-16	6711-6713	as	_
40-17	6714-6717	0.2	_
40-18	6718-6720	mm	_
40-19	6721-6722	)	_
40-20	6723-6725	on	_
40-21	6726-6733	resting	_
40-22	6734-6744	functional	_
40-23	6745-6757	connectivity	_
40-24	6758-6759	,	_
40-25	6760-6762	we	_
40-26	6763-6775	additionally	_
40-27	6776-6786	calculated	_
40-28	6787-6791	mean	_
40-29	6792-6806	Frame-by-Frame	_
40-30	6807-6811	head	_
40-31	6812-6824	displacement	_
40-32	6825-6826	(	_
40-33	6827-6829	FD	_
40-34	6830-6831	)	_
40-35	6832-6834	to	_
40-36	6835-6842	compare	_
40-37	6843-6846	the	_
40-38	6847-6850	two	_
40-39	6851-6857	groups	_
40-40	6858-6861	and	_
40-41	6862-6865	for	_
40-42	6866-6876	subsequent	_
40-43	6877-6880	use	_
40-44	6881-6883	as	_
40-45	6884-6885	a	_
40-46	6886-6894	nuisance	_
40-47	6895-6904	covariate	_
40-48	6905-6907	at	_
40-49	6908-6911	the	_
40-50	6912-6918	second	_
40-51	6919-6924	level	_
40-52	6925-6933	analysis	_
40-53	6934-6935	(	_
40-54	6936-6939	see	_
40-55	6940-6945	below	_
40-56	6946-6947	)	_
40-57	6948-6949	.	_

41-1	6950-6956	Images	_
41-2	6957-6961	were	_
41-3	6962-6966	then	_
41-4	6967-6976	detrended	_
41-5	6977-6979	to	_
41-6	6980-6986	remove	_
41-7	6987-6993	linear	_
41-8	6994-7000	trends	_
41-9	7001-7004	due	_
41-10	7005-7007	to	_
41-11	7008-7015	scanner	_
41-12	7016-7021	drift	_
41-13	7022-7023	;	_
41-14	7024-7033	band-pass	_
41-15	7034-7042	filtered	_
41-16	7043-7044	(	_
41-17	7045-7055	0.01–0.1Hz	_
41-18	7056-7057	)	_
41-19	7058-7060	to	_
41-20	7061-7067	remove	_
41-21	7068-7075	scanner	_
41-22	7076-7079	and	_
41-23	7080-7098	cardio-respiratory	_
41-24	7099-7104	noise	_
41-25	7105-7106	.	_

42-1	7107-7113	Tissue	_
42-2	7114-7119	based	_
42-3	7120-7127	signals	_
42-4	7128-7132	such	_
42-5	7133-7135	as	_
42-6	7136-7141	white	_
42-7	7142-7148	matter	_
42-8	7149-7150	,	_
42-9	7151-7154	CSF	_
42-10	7155-7158	and	_
42-11	7159-7165	global	_
42-12	7166-7172	signal	_
42-13	7173-7177	were	_
42-14	7178-7182	used	_
42-15	7183-7185	as	_
42-16	7186-7194	nuisance	_
42-17	7195-7205	regressors	_
42-18	7206-7208	to	_
42-19	7209-7215	remove	_
42-20	7216-7219	the	_
42-21	7220-7227	sources	_
42-22	7228-7230	of	_
42-23	7231-7239	spurious	_
42-24	7240-7248	variance	_
42-25	7249-7252	and	_
42-26	7253-7258	their	_
42-27	7259-7267	temporal	_
42-28	7268-7279	derivatives	_
42-29	7280-7284	were	_
42-30	7285-7289	also	_
42-31	7290-7297	removed	_
42-32	7298-7302	from	_
42-33	7303-7306	the	_
42-34	7307-7311	data	_
42-35	7312-7319	through	_
42-36	7320-7326	linear	_
42-37	7327-7337	regression	_
42-38	7338-7339	.	_

43-1	7340-7348	Smoothed	_
43-2	7349-7359	normalized	_
43-3	7360-7366	images	_
43-4	7367-7371	were	_
43-5	7372-7379	entered	_
43-6	7380-7384	into	_
43-7	7385-7395	seed-based	_
43-8	7396-7402	region	_
43-9	7403-7405	of	_
43-10	7406-7414	interest	_
43-11	7415-7416	(	_
43-12	7417-7420	ROI	_
43-13	7421-7422	)	_
43-14	7423-7431	analysis	_
43-15	7432-7436	with	_
43-16	7437-7446	amygdalae	_
43-17	7447-7449	as	_
43-18	7450-7455	seeds	_
43-19	7456-7457	.	_

44-1	7458-7459	A	_
44-2	7460-7477	cross-correlation	_
44-3	7478-7481	map	_
44-4	7482-7485	was	_
44-5	7486-7497	constructed	_
44-6	7498-7500	by	_
44-7	7501-7506	doing	_
44-8	7507-7517	voxel-wise	_
44-9	7518-7529	correlation	_
44-10	7530-7537	between	_
44-11	7538-7541	the	_
44-12	7542-7550	temporal	_
44-13	7551-7558	signals	_
44-14	7559-7563	from	_
44-15	7564-7568	both	_
44-16	7569-7572	the	_
44-17	7573-7578	right	_
44-18	7579-7582	and	_
44-19	7583-7587	left	_
44-20	7588-7596	amygdala	_
44-21	7597-7600	and	_
44-22	7601-7605	each	_
44-23	7606-7611	voxel	_
44-24	7612-7614	in	_
44-25	7615-7618	the	_
44-26	7619-7624	brain	_
44-27	7625-7626	.	_

45-1	7627-7630	The	_
45-2	7631-7636	right	_
45-3	7637-7640	and	_
45-4	7641-7645	left	_
45-5	7646-7655	amygdalae	_
45-6	7656-7660	were	_
45-7	7661-7669	selected	_
45-8	7670-7672	as	_
45-9	7673-7677	ROIs	_
45-10	7678-7679	(	_
45-11	7680-7683	AAL	_
45-12	7684-7689	atlas	_
45-13	7690-7691	)	_
45-14	7692-7697	based	_
45-15	7698-7700	on	_
45-16	7701-7706	prior	_
45-17	7707-7711	work	_
45-18	7712-7723	implicating	_
45-19	7724-7729	their	_
45-20	7730-7741	involvement	_
45-21	7742-7744	in	_
45-22	7745-7748	the	_
45-23	7749-7764	pathophysiology	_
45-24	7765-7767	of	_
45-25	7768-7774	stress	_
45-26	7775-7776	,	_
45-27	7777-7783	trauma	_
45-28	7784-7792	exposure	_
45-29	7793-7794	,	_
45-30	7795-7798	and	_
45-31	7799-7808	addiction	_
45-32	7809-7810	.	_

46-1	7811-7813	We	_
46-2	7814-7822	examined	_
46-3	7823-7835	connectivity	_
46-4	7836-7839	for	_
46-5	7840-7844	each	_
46-6	7845-7849	side	_
46-7	7850-7852	of	_
46-8	7853-7856	the	_
46-9	7857-7865	amygdala	_
46-10	7866-7876	separately	_
46-11	7877-7878	,	_
46-12	7879-7881	as	_
46-13	7882-7885	the	_
46-14	7886-7891	human	_
46-15	7892-7902	literature	_
46-16	7903-7906	has	_
46-17	7907-7917	documented	_
46-18	7918-7929	differences	_
46-19	7930-7932	in	_
46-20	7933-7943	anatomical	_
46-21	7944-7955	connections	_
46-22	7956-7959	for	_
46-23	7960-7963	the	_
46-24	7964-7968	left	_
46-25	7969-7972	and	_
46-26	7973-7978	right	_
46-27	7979-7987	amygdala	_
46-28	7988-7989	.	_

47-1	7990-7993	The	_
47-2	7994-8003	resulting	_
47-3	8004-8015	correlation	_
47-4	8016-8019	map	_
47-5	8020-8024	from	_
47-6	8025-8029	each	_
47-7	8030-8041	participant	_
47-8	8042-8045	was	_
47-9	8046-8055	converted	_
47-10	8056-8058	to	_
47-11	8059-8060	Z	_
47-12	8061-8064	map	_
47-13	8065-8070	using	_
47-14	8071-8077	Fisher	_
47-15	8078-8079	’	_
47-16	8080-8081	s	_
47-17	8082-8088	r-to-z	_
47-18	8089-8103	transformation	_
47-19	8104-8106	in	_
47-20	8107-8112	order	_
47-21	8113-8115	to	_
47-22	8116-8123	improve	_
47-23	8124-8127	the	_
47-24	8128-8137	normality	_
47-25	8138-8140	of	_
47-26	8141-8144	the	_
47-27	8145-8156	correlation	_
47-28	8157-8169	coefficients	_
47-29	8170-8171	.	_

48-1	8172-8175	The	_
48-2	8176-8177	Z	_
48-3	8178-8182	maps	_
48-4	8183-8187	were	_
48-5	8188-8192	then	_
48-6	8193-8201	analyzed	_
48-7	8202-8204	in	_
48-8	8205-8206	a	_
48-9	8207-8221	random-effects	_
48-10	8222-8227	model	_
48-11	8228-8230	in	_
48-12	8231-8235	SPM8	_
48-13	8236-8238	to	_
48-14	8239-8245	reveal	_
48-15	8246-8249	any	_
48-16	8250-8261	differences	_
48-17	8262-8264	in	_
48-18	8265-8269	RSFC	_
48-19	8270-8277	between	_
48-20	8278-8281	the	_
48-21	8282-8288	Trauma	_
48-22	8289-8292	and	_
48-23	8293-8302	No-Trauma	_
48-24	8303-8312	subgroups	_
48-25	8313-8314	(	_
48-26	8315-8318	see	_
48-27	8319-8324	below	_
48-28	8325-8328	for	_
48-29	8329-8342	trauma-status	_
48-30	8343-8356	determination	_
48-31	8357-8358	)	_
48-32	8359-8360	.	_

49-1	8361-8363	In	_
49-2	8364-8367	all	_
49-3	8368-8371	the	_
49-4	8372-8377	group	_
49-5	8378-8386	analysis	_
49-6	8387-8388	,	_
49-7	8389-8393	mean	_
49-8	8394-8396	FD	_
49-9	8397-8400	was	_
49-10	8401-8408	entered	_
49-11	8409-8411	as	_
49-12	8412-8413	a	_
49-13	8414-8422	nuisance	_
49-14	8423-8431	variable	_
49-15	8432-8434	to	_
49-16	8435-8442	control	_
49-17	8443-8446	for	_
49-18	8447-8459	participants	_
49-19	8460-8461	’	_
49-20	8462-8466	head	_
49-21	8467-8473	motion	_
49-22	8474-8475	.	_

50-1	8476-8481	Based	_
50-2	8482-8484	on	_
50-3	8485-8490	prior	_
50-4	8491-8495	work	_
50-5	8496-8497	,	_
50-6	8498-8500	we	_
50-7	8501-8508	further	_
50-8	8509-8520	constrained	_
50-9	8521-8524	the	_
50-10	8525-8531	voxels	_
50-11	8532-8536	that	_
50-12	8537-8539	we	_
50-13	8540-8547	queried	_
50-14	8548-8550	in	_
50-15	8551-8559	relation	_
50-16	8560-8562	to	_
50-17	8563-8566	the	_
50-18	8567-8575	amygdala	_
50-19	8576-8577	,	_
50-20	8578-8583	based	_
50-21	8584-8586	on	_
50-22	8587-8588	a	_
50-23	8589-8593	mask	_
50-24	8594-8598	that	_
50-25	8599-8607	includes	_
50-26	8608-8618	mesolimbic	_
50-27	8619-8626	regions	_
50-28	8627-8628	(	_
50-29	8629-8637	amygdala	_
50-30	8638-8639	,	_
50-31	8640-8647	ventral	_
50-32	8648-8657	tegmental	_
50-33	8658-8671	area/midbrain	_
50-34	8672-8673	,	_
50-35	8674-8681	ventral	_
50-36	8682-8690	striatum	_
50-37	8691-8692	,	_
50-38	8693-8699	caudal	_
50-39	8700-8713	orbitofrontal	_
50-40	8714-8720	cortex	_
50-41	8721-8722	)	_
50-42	8723-8724	,	_
50-43	8725-8728	and	_
50-44	8729-8734	three	_
50-45	8735-8740	other	_
50-46	8741-8759	addiction-relevant	_
50-47	8760-8767	regions	_
50-48	8768-8777	including	_
50-49	8778-8781	the	_
50-50	8782-8788	insula	_
50-51	8789-8790	,	_
50-52	8791-8797	dorsal	_
50-53	8798-8806	striatum	_
50-54	8807-8808	,	_
50-55	8809-8812	and	_
50-56	8813-8821	thalamus	_
50-57	8822-8823	.	_

51-1	8824-8827	The	_
51-2	8828-8832	mask	_
51-3	8833-8842	including	_
51-4	8843-8846	our	_
51-5	8847-8848	a	_
51-6	8849-8855	priori	_
51-7	8856-8860	ROIs	_
51-8	8861-8862	,	_
51-9	8863-8866	was	_
51-10	8867-8874	created	_
51-11	8875-8880	using	_
51-12	8881-8895	Harvard-Oxford	_
51-13	8896-8904	Cortical	_
51-14	8905-8915	Structural	_
51-15	8916-8921	Atlas	_
51-16	8922-8923	(	_
51-17	8924-8928	FMRI	_
51-18	8929-8931	of	_
51-19	8932-8935	the	_
51-20	8936-8941	Brain	_
51-21	8942-8943	[	_
51-22	8944-8949	FMRIB	_
51-23	8950-8951	]	_
51-24	8952-8960	Software	_
51-25	8961-8968	Library	_
51-26	8969-8970	,	_
51-27	8971-8977	Oxford	_
51-28	8978-8984	Centre	_
51-29	8985-8988	for	_
51-30	8989-8994	FMIRB	_
51-31	8995-8996	)	_
51-32	8997-9001	with	_
51-33	9002-9003	a	_
51-34	9004-9015	probability	_
51-35	9016-9025	threshold	_
51-36	9026-9033	ranging	_
51-37	9034-9041	between	_
51-38	9042-9047	10–25	_
51-39	9048-9049	%	_
51-40	9050-9051	.	_

52-1	9052-9055	For	_
52-2	9056-9059	the	_
52-3	9060-9068	purposes	_
52-4	9069-9071	of	_
52-5	9072-9075	the	_
52-6	9076-9083	current	_
52-7	9084-9089	paper	_
52-8	9090-9091	,	_
52-9	9092-9096	this	_
52-10	9097-9103	limbic	_
52-11	9104-9108	mask	_
52-12	9109-9111	is	_
52-13	9112-9119	treated	_
52-14	9120-9122	as	_
52-15	9123-9126	the	_
52-16	9127-9131	unit	_
52-17	9132-9134	of	_
52-18	9135-9143	analysis	_
52-19	9144-9145	(	_
52-20	9146-9147	a	_
52-21	9148-9154	single	_
52-22	9155-9161	region	_
52-23	9162-9164	of	_
52-24	9165-9173	interest	_
52-25	9174-9175	)	_
52-26	9176-9177	.	_

53-1	9178-9188	Individual	_
53-2	9189-9198	sub-group	_
53-3	9199-9203	maps	_
53-4	9204-9208	were	_
53-5	9209-9220	thresholded	_
53-6	9221-9223	at	_
53-7	9224-9227	FWE	_
53-8	9228-9237	corrected	_
53-9	9238-9239	,	_
53-10	9240-9241	p	_
53-11	9242-9243	<	_
53-12	9244-9248	0.05	_
53-13	9249-9250	,	_
53-14	9251-9254	and	_
53-15	9255-9258	the	_
53-16	9259-9264	group	_
53-17	9265-9273	contrast	_
53-18	9274-9278	maps	_
53-19	9279-9282	are	_
53-20	9283-9290	cluster	_
53-21	9291-9300	corrected	_
53-22	9301-9303	at	_
53-23	9304-9305	p	_
53-24	9306-9307	<	_
53-25	9308-9312	0.05	_
53-26	9313-9317	with	_
53-27	9318-9321	425	_
53-28	9322-9332	contiguous	_
53-29	9333-9339	voxels	_
53-30	9340-9345	based	_
53-31	9346-9348	on	_
53-32	9349-9352	the	_
53-33	9353-9361	recently	_
53-34	9362-9370	debugged	_
53-35	9371-9378	version	_
53-36	9379-9381	of	_
53-37	9382-9392	3dClustSim	_
53-38	9393-9398	using	_
53-39	9399-9414	autocorrelation	_
53-40	9415-9423	function	_
53-41	9424-9425	(	_
53-42	9426-9429	ACF	_
53-43	9430-9431	)	_
53-44	9432-9438	option	_
53-45	9439-9441	in	_
53-46	9442-9454	AFNI_17.2.05	_
53-47	9455-9456	.	_

54-1	9457-9460	ACF	_
54-2	9461-9464	was	_
54-3	9465-9475	calculated	_
54-4	9476-9478	by	_
54-5	9479-9486	running	_
54-6	9487-9494	3dFWHMx	_
54-7	9495-9497	on	_
54-8	9498-9501	the	_
54-9	9502-9510	residual	_
54-10	9511-9516	image	_
54-11	9517-9519	at	_
54-12	9520-9525	group	_
54-13	9526-9531	level	_
54-14	9532-9533	.	_

55-1	9534-9537	2.5	_
55-2	9538-9544	Trauma	_
55-3	9545-9551	Versus	_
55-4	9552-9561	No-Trauma	_
55-5	9562-9571	Subgroups	_
55-6	9572-9574	Of	_
55-7	9575-9578	the	_
55-8	9579-9581	34	_
55-9	9582-9594	participants	_
55-10	9595-9596	,	_
55-11	9597-9599	18	_
55-12	9600-9604	were	_
55-13	9605-9615	designated	_
55-14	9616-9618	to	_
55-15	9619-9622	the	_
55-16	9623-9624	“	_
55-17	9625-9631	Trauma	_
55-18	9632-9633	”	http://maven.renci.org/NeuroBridge/neurobridge#Thing
55-19	9634-9639	group	_
55-20	9640-9645	while	_
55-21	9646-9648	16	_
55-22	9649-9653	were	_
55-23	9654-9664	designated	_
55-24	9665-9667	as	_
55-25	9668-9671	the	_
55-26	9672-9673	“	_
55-27	9674-9683	No-Trauma	_
55-28	9684-9685	”	http://maven.renci.org/NeuroBridge/neurobridge#ParallelGroupTrial
55-29	9686-9691	group	http://maven.renci.org/NeuroBridge/neurobridge#ParallelGroupTrial
55-30	9692-9693	.	_

56-1	9694-9707	Determination	_
56-2	9708-9710	of	_
56-3	9711-9717	trauma	_
56-4	9718-9724	status	_
56-5	9725-9728	was	_
56-6	9729-9734	based	_
56-7	9735-9737	on	_
56-8	9738-9750	participants	_
56-9	9751-9752	’	_
56-10	9753-9761	response	_
56-11	9762-9764	to	_
56-12	9765-9768	two	_
56-13	9769-9777	measures	_
56-14	9778-9779	.	_

57-1	9780-9783	The	_
57-2	9784-9789	first	_
57-3	9790-9793	was	_
57-4	9794-9797	the	_
57-5	9798-9801	ASI	_
57-6	9802-9812	supplement	_
57-7	9813-9814	–	_
57-8	9815-9819	PTSD	http://maven.renci.org/NeuroBridge/neurobridge#PostTraumaticStressDisorder
57-9	9820-9833	questionnaire	http://maven.renci.org/NeuroBridge/neurobridge#PostTraumaticStressDisorder
57-10	9834-9835	,	_
57-11	9836-9841	which	_
57-12	9842-9848	probes	_
57-13	9849-9856	whether	_
57-14	9857-9860	one	_
57-15	9861-9864	has	_
57-16	9865-9866	‘	_
57-17	9867-9871	ever	_
57-18	9872-9883	experienced	_
57-19	9884-9893	something	_
57-20	9894-9896	so	_
57-21	9897-9908	frightening	_
57-22	9909-9910	,	_
57-23	9911-9919	horrible	_
57-24	9920-9921	,	_
57-25	9922-9924	or	_
57-26	9925-9934	upsetting	_
57-27	9935-9939	that	_
57-28	9940-9946	others	_
57-29	9947-9953	rarely	_
57-30	9954-9956	go	_
57-31	9957-9964	through	_
57-32	9965-9966	’	_
57-33	9967-9968	.	_

58-1	9969-9974	Prior	_
58-2	9975-9982	studies	_
58-3	9983-9987	have	_
58-4	9988-9992	used	_
58-5	9993-9996	the	_
58-6	9997-10000	ASI	_
58-7	10001-10003	to	_
58-8	10004-10011	measure	_
58-9	10012-10018	trauma	_
58-10	10019-10027	exposure	_
58-11	10028-10029	.	_

59-1	10030-10036	Trauma	_
59-2	10037-10043	status	_
59-3	10044-10047	was	_
59-4	10048-10055	further	_
59-5	10056-10063	queried	_
59-6	10064-10066	by	_
59-7	10067-10079	participants	_
59-8	10080-10081	’	_
59-9	10082-10091	responses	_
59-10	10092-10094	to	_
59-11	10095-10098	the	_
59-12	10099-10108	clinician	_
59-13	10109-10121	administered	_
59-14	10122-10126	MINI	_
59-15	10127-10128	,	_
59-16	10129-10134	which	_
59-17	10135-10143	assesses	_
59-18	10144-10147	for	_
59-19	10148-10154	trauma	_
59-20	10155-10163	exposure	_
59-21	10164-10166	as	_
59-22	10167-10168	a	_
59-23	10169-10180	preliminary	_
59-24	10181-10190	criterion	_
59-25	10191-10194	for	_
59-26	10195-10199	PTSD	http://maven.renci.org/NeuroBridge/neurobridge#PostTraumaticStressDisorder
59-27	10200-10209	diagnosis	_
59-28	10210-10211	.	_

60-1	10212-10215	All	_
60-2	10216-10228	participants	_
60-3	10229-10231	in	_
60-4	10232-10235	the	_
60-5	10236-10242	Trauma	_
60-6	10243-10248	group	_
60-7	10249-10257	endorsed	_
60-8	10258-10264	trauma	_
60-9	10265-10273	exposure	_
60-10	10274-10276	on	_
60-11	10277-10281	both	_
60-12	10282-10285	the	_
60-13	10286-10290	MINI	_
60-14	10291-10294	and	_
60-15	10295-10298	ASI	_
60-16	10299-10300	.	_

61-1	10301-10303	It	_
61-2	10304-10306	is	_
61-3	10307-10312	worth	_
61-4	10313-10319	noting	_
61-5	10320-10324	that	_
61-6	10325-10326	,	_
61-7	10327-10332	while	_
61-8	10333-10336	the	_
61-9	10337-10343	parent	_
61-10	10344-10349	study	_
61-11	10350-10358	excluded	_
61-12	10359-10365	Axis-I	_
61-13	10366-10375	diagnosis	_
61-14	10376-10385	including	_
61-15	10386-10390	PTSD	http://maven.renci.org/NeuroBridge/neurobridge#PostTraumaticStressDisorder
61-16	10391-10392	,	_
61-17	10393-10399	Trauma	_
61-18	10400-10412	participants	_
61-19	10413-10415	in	_
61-20	10416-10420	this	_
61-21	10421-10426	study	_
61-22	10427-10435	endorsed	_
61-23	10436-10442	trauma	_
61-24	10443-10451	exposure	_
61-25	10452-10455	but	_
61-26	10456-10459	did	_
61-27	10460-10463	not	_
61-28	10464-10468	meet	_
61-29	10469-10477	criteria	_
61-30	10478-10481	for	_
61-31	10482-10486	PTSD	http://maven.renci.org/NeuroBridge/neurobridge#PostTraumaticStressDisorder
61-32	10487-10488	.	_

